复星医药是国内领先的创新型国际化医药健康产业集团,2025年拿下了优异的成绩单:2款1类新药获批并新增进入了国家医保目录,51个仿制药新品上市进一步丰富产品矩阵;前三季在中国三大终端六大市场,集团有33个产品销售额超过1亿元,最高涨幅达1589%,2大千亿市场高位领先,实力强劲。2026年开局,复星医药已拿下2款仿制药新品,2款新药首次获批临床,未来可期。新品大丰收!2款1类新药、53个仿制药获批...
Source Link复星医药是国内领先的创新型国际化医药健康产业集团,2025年拿下了优异的成绩单:2款1类新药获批并新增进入了国家医保目录,51个仿制药新品上市进一步丰富产品矩阵;前三季在中国三大终端六大市场,集团有33个产品销售额超过1亿元,最高涨幅达1589%,2大千亿市场高位领先,实力强劲。2026年开局,复星医药已拿下2款仿制药新品,2款新药首次获批临床,未来可期。新品大丰收!2款1类新药、53个仿制药获批...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.